Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Adaptimmune Therapeutics Plc's Business Segments
Adaptimmune Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Product revenue net
Total Revenue
$ 14
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product revenue net81%
- Development revenue19%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue net | $ 11 | 81% |
| Development revenue | $ 3 | 19% |
Revenue by Product & Service Category - FY
- Product81%
- Development revenue19%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 11 | 81% |
| Development revenue | $ 3 | 19% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product revenue net81%
- Development revenue19%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product revenue net | $ 11 | 81% |
| Development revenue | $ 3 | 19% |
Description of Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc is a clinical-stage biotechnology company primarily focused on the development of novel immunotherapies for the treatment of cancer. The company was founded in 2008 and is headquartered in Abingdon, Oxfordshire, United Kingdom.
The core focus of Adaptimmune is to harness the power of the immune system to recognize and eliminate cancer cells. The company's main technology platform is called SPEAR (Specific Peptide Enhanced Affinity Receptor), which involves engineering T-cell receptors (TCRs) to target and destroy cancer cells.
Adaptimmune's proprietary SPEAR TCR technology enables the genetic modification of a patient's T-cells to express new receptors that can recognize specific cancer antigens. These modified T-cells are then infused back into the patient's body, where they can identify and destroy cancer cells that harbor the targeted antigens.
The company's pipeline includes multiple product candidates targeting various types of cancer, including solid tumors and hematological malignancies. Adaptimmune has developed partnerships with various pharmaceutical companies, including GlaxoSmithKline (GSK) and Astellas Pharma, to further advance its product candidates and access additional resources for clinical development.
Adaptimmune has conducted numerous clinical trials to evaluate the safety and efficacy of its immunotherapies. These studies have shown promising results, with some patients achieving complete or partial responses. The company is also actively engaged in preclinical research to expand the application of its technology and explore combination therapies.
In addition to its flagship SPEAR TCR platform, Adaptimmune is also developing other immunotherapy technologies, such as its armored CAR-T (chimeric antigen receptor T-cell) platform. CAR-T therapies involve engineering T-cells to express receptors that are designed to target specific antigens on cancer cells.
Adaptimmune is committed to advancing its therapies and improving outcomes for patients with cancer. The company has a team of experienced scientists, clinicians, and industry experts dedicated to research, development, and commercialization. It collaborates with academic institutions, healthcare organizations, and regulatory authorities to ensure the safety and efficacy of its therapies.
As a publicly traded company, Adaptimmune is listed on the NASDAQ stock exchange under the ticker symbol ADAP and the London Stock Exchange under the ticker symbol ADAP. The company regularly reports its financial results and provides updates on its clinical programs and strategic initiatives to its shareholders and the broader financial community.
Overall, Adaptimmune Therapeutics Plc is at the forefront of developing innovative immunotherapies that hold significant potential to revolutionize cancer treatment. With a robust pipeline, strong partnerships, and a dedicated team, the company continues to make strides in its mission to provide novel therapies for patients battling cancer.
The core focus of Adaptimmune is to harness the power of the immune system to recognize and eliminate cancer cells. The company's main technology platform is called SPEAR (Specific Peptide Enhanced Affinity Receptor), which involves engineering T-cell receptors (TCRs) to target and destroy cancer cells.
Adaptimmune's proprietary SPEAR TCR technology enables the genetic modification of a patient's T-cells to express new receptors that can recognize specific cancer antigens. These modified T-cells are then infused back into the patient's body, where they can identify and destroy cancer cells that harbor the targeted antigens.
The company's pipeline includes multiple product candidates targeting various types of cancer, including solid tumors and hematological malignancies. Adaptimmune has developed partnerships with various pharmaceutical companies, including GlaxoSmithKline (GSK) and Astellas Pharma, to further advance its product candidates and access additional resources for clinical development.
Adaptimmune has conducted numerous clinical trials to evaluate the safety and efficacy of its immunotherapies. These studies have shown promising results, with some patients achieving complete or partial responses. The company is also actively engaged in preclinical research to expand the application of its technology and explore combination therapies.
In addition to its flagship SPEAR TCR platform, Adaptimmune is also developing other immunotherapy technologies, such as its armored CAR-T (chimeric antigen receptor T-cell) platform. CAR-T therapies involve engineering T-cells to express receptors that are designed to target specific antigens on cancer cells.
Adaptimmune is committed to advancing its therapies and improving outcomes for patients with cancer. The company has a team of experienced scientists, clinicians, and industry experts dedicated to research, development, and commercialization. It collaborates with academic institutions, healthcare organizations, and regulatory authorities to ensure the safety and efficacy of its therapies.
As a publicly traded company, Adaptimmune is listed on the NASDAQ stock exchange under the ticker symbol ADAP and the London Stock Exchange under the ticker symbol ADAP. The company regularly reports its financial results and provides updates on its clinical programs and strategic initiatives to its shareholders and the broader financial community.
Overall, Adaptimmune Therapeutics Plc is at the forefront of developing innovative immunotherapies that hold significant potential to revolutionize cancer treatment. With a robust pipeline, strong partnerships, and a dedicated team, the company continues to make strides in its mission to provide novel therapies for patients battling cancer.
Adaptimmune Therapeutics Plc is a prominent biopharmaceutical company dedicated to developing innovative cell therapies targeting various cancers. Its offerings can be categorized into three core segments: research and development, clinical trials, and commercial products and services. Below is an extensive description of each segment along with the companys flagship products and services.
1. Research & Development:
Adaptimmune allocates significant resources to research and development, focusing on advancing its proprietary T-cell receptor (TCR) technology. The aim is to harness the body’s immune system to identify and eliminate specific cancer cells, creating personalized treatment modalities for patients. Key areas of focus within R&D include:
- TCR Technology Platform: Adaptimmunes unique technology allows for the engineering of T-cells to express T-cell receptors that specifically recognize cancer-associated antigens. This precision targeting enhances the potential for effective treatment with reduced off-target effects.
- Antigen Discovery: The process involves the identification of relevant antigens present on cancer cells, which are the targets for the engineered T-cells. Adaptimmune employs sophisticated bioinformatics and molecular biology techniques to discover novel antigens that can serve as therapeutic targets.
- Preclinical Studies: Before moving into clinical trials, Adaptimmune conducts extensive preclinical studies to evaluate the therapeutic candidates safety, efficacy, and pharmacodynamics through various in vitro and in vivo models.
- Collaborations and Partnerships: The company often engages with academic institutions, research organizations, and biopharmaceutical partners to enhance its research efforts, access new technologies, and accelerate the development process.
Clinical Trials:
Adaptimmune is deeply committed to conducting comprehensive clinical trials to assess the safety and efficacy of its therapeutic candidates. The clinical trial process encompasses several phases:
- Phases of Clinical Trials: Adaptimmune’s products typically undergo Phase 1 (safety and dosage), Phase 2 (efficacy and side effects), and Phase 3 (comparison to standard treatments) trials, each designed to build upon the findings of the previous phase.
- Global Collaborations: The company collaborates with esteemed academic and medical institutions worldwide, which allows for a diverse patient population and the collection of robust clinical data.
- Regulatory Engagement: Adaptimmune works closely with regulatory agencies to ensure compliance with all guidelines and to facilitate the approval process. This involves submitting Investigational New Drug (IND) applications and ongoing communication to keep pace with regulatory changes.
- Clinical Trial Infrastructure: Adaptimmune invests in establishing state-of-the-art infrastructure to support its clinical programs, including specialized facilities for manufacturing T-cells and managing clinical data.
Commercial Products and Services:
Adaptimmune aims to bring its innovative therapies to the forefront of cancer treatment, currently offering two primary commercial products:
a. ADP-A2M4:
- Indications and Mechanism: ADP-A2M4 is an autologous T-cell therapy targeting the MAGE-A4 antigen, which is expressed in multiple solid tumors such as synovial sarcoma and certain head and neck cancers. This therapy is designed to modify a patient’s T-cells to recognize and attack cancer cells that express this specific protein.
- Clinical Development: The therapy has shown promise in clinical trials, with a focus on safety data and initial efficacy results providing evidence of its potential benefit in treating these aggressive cancers.
b. ADP-A2AFP:
- Indications and Mechanism: ADP-A2AFP targets alpha-fetoprotein (AFP), an antigen implicated in hepatocellular carcinoma (HCC) and other AFP-expressing malignancies. This therapy aims to empower the immune system to selectively eradicate cells that produce AFP.
- Clinical Development: Adaptimmune conducts trials to explore the efficacy of ADP-A2AFP in treating HCC, with results indicating a potential improvement in patient outcomes.
Specialized Services:
In addition to its therapeutic products, Adaptimmune provides a range of specialized services essential for the effective delivery of its cell therapies, including:
- T-cell Collection: Expertise in the collection of T-cells from patients, which is a critical starting point for creating the engineered cell therapies.
- Manufacturing Capabilities: Advanced facilities for the manufacturing of genetically modified T-cells that adhere to stringent regulatory standards, ensuring safety and consistency in product quality.
- Delivery and Administration: Support for healthcare providers in administering these therapies to patients effectively, including training and guidelines for the clinical use of the products.
Summary:
Adaptimmune Therapeutics Plc offers a comprehensive approach to cancer treatment through its substantial investments in research and development, rigorous clinical trial processes, and innovative cell therapy products. By focusing on TCR technology and customizing therapies to target distinct cancer antigens, the company continues to push the boundaries in the field of cancer therapy, aiming to improve diagnosis and treatments for patients worldwide.
1. Research & Development:
Adaptimmune allocates significant resources to research and development, focusing on advancing its proprietary T-cell receptor (TCR) technology. The aim is to harness the body’s immune system to identify and eliminate specific cancer cells, creating personalized treatment modalities for patients. Key areas of focus within R&D include:
- TCR Technology Platform: Adaptimmunes unique technology allows for the engineering of T-cells to express T-cell receptors that specifically recognize cancer-associated antigens. This precision targeting enhances the potential for effective treatment with reduced off-target effects.
- Antigen Discovery: The process involves the identification of relevant antigens present on cancer cells, which are the targets for the engineered T-cells. Adaptimmune employs sophisticated bioinformatics and molecular biology techniques to discover novel antigens that can serve as therapeutic targets.
- Preclinical Studies: Before moving into clinical trials, Adaptimmune conducts extensive preclinical studies to evaluate the therapeutic candidates safety, efficacy, and pharmacodynamics through various in vitro and in vivo models.
- Collaborations and Partnerships: The company often engages with academic institutions, research organizations, and biopharmaceutical partners to enhance its research efforts, access new technologies, and accelerate the development process.
Clinical Trials:
Adaptimmune is deeply committed to conducting comprehensive clinical trials to assess the safety and efficacy of its therapeutic candidates. The clinical trial process encompasses several phases:
- Phases of Clinical Trials: Adaptimmune’s products typically undergo Phase 1 (safety and dosage), Phase 2 (efficacy and side effects), and Phase 3 (comparison to standard treatments) trials, each designed to build upon the findings of the previous phase.
- Global Collaborations: The company collaborates with esteemed academic and medical institutions worldwide, which allows for a diverse patient population and the collection of robust clinical data.
- Regulatory Engagement: Adaptimmune works closely with regulatory agencies to ensure compliance with all guidelines and to facilitate the approval process. This involves submitting Investigational New Drug (IND) applications and ongoing communication to keep pace with regulatory changes.
- Clinical Trial Infrastructure: Adaptimmune invests in establishing state-of-the-art infrastructure to support its clinical programs, including specialized facilities for manufacturing T-cells and managing clinical data.
Commercial Products and Services:
Adaptimmune aims to bring its innovative therapies to the forefront of cancer treatment, currently offering two primary commercial products:
a. ADP-A2M4:
- Indications and Mechanism: ADP-A2M4 is an autologous T-cell therapy targeting the MAGE-A4 antigen, which is expressed in multiple solid tumors such as synovial sarcoma and certain head and neck cancers. This therapy is designed to modify a patient’s T-cells to recognize and attack cancer cells that express this specific protein.
- Clinical Development: The therapy has shown promise in clinical trials, with a focus on safety data and initial efficacy results providing evidence of its potential benefit in treating these aggressive cancers.
b. ADP-A2AFP:
- Indications and Mechanism: ADP-A2AFP targets alpha-fetoprotein (AFP), an antigen implicated in hepatocellular carcinoma (HCC) and other AFP-expressing malignancies. This therapy aims to empower the immune system to selectively eradicate cells that produce AFP.
- Clinical Development: Adaptimmune conducts trials to explore the efficacy of ADP-A2AFP in treating HCC, with results indicating a potential improvement in patient outcomes.
Specialized Services:
In addition to its therapeutic products, Adaptimmune provides a range of specialized services essential for the effective delivery of its cell therapies, including:
- T-cell Collection: Expertise in the collection of T-cells from patients, which is a critical starting point for creating the engineered cell therapies.
- Manufacturing Capabilities: Advanced facilities for the manufacturing of genetically modified T-cells that adhere to stringent regulatory standards, ensuring safety and consistency in product quality.
- Delivery and Administration: Support for healthcare providers in administering these therapies to patients effectively, including training and guidelines for the clinical use of the products.
Summary:
Adaptimmune Therapeutics Plc offers a comprehensive approach to cancer treatment through its substantial investments in research and development, rigorous clinical trial processes, and innovative cell therapy products. By focusing on TCR technology and customizing therapies to target distinct cancer antigens, the company continues to push the boundaries in the field of cancer therapy, aiming to improve diagnosis and treatments for patients worldwide.